You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
468 Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 status

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023390031
Dec 2023289017
Jan 202412007
Feb 202417409
Mar 2024266018
Apr 2024182024
May 202415708
Jun 2024133015
Jul 2024148018
Aug 2024188010
Sep 202413606
Oct 2024168018
Nov 2024196016
Dec 2024140019
Jan 2025185029
Feb 202554020
Mar 20250013
Apr 20250015
May 20250013
Jun 2025008
Total29260314